Background: Patients who have undergone endoscopic resection of early gastric
| INTRODUCTION
Advances in endoscopic techniques have greatly improved the detection and treatment of early gastric cancer (EGC). 1 Although endoscopic resection is accepted as the curative treatment modality for EGC, the remnant gastric mucosa has a high risk of developing metachronous gastric neoplasm. 2 Many studies have shown persistent Helicobacter pylori (H. pylori) infection, an older age, severe atrophy, and a lower serum pepsinogen (PG) I level or serum ratio of PGI:PGII as risk factors of metachronous gastric neoplasm. [3] [4] [5] Several studies using meta-analysis have shown that H. pylori eradication reduces the risk of development of metachronous gastric neoplasm. 3, [5] [6] [7] However, metachronous gastric neoplasm can occur after successful H. Pylori eradication because the remaining gastric mucosal atrophy is an important risk factor for the development of metachronous gastric neoplasm. 8 Previous studies have investigated various methodologies used to evaluate the extent of gastric mucosal status, such as endoscopic findings and histopathology of endoscopic biopsy samples. 7 However, both methods have limitations in terms of how well they evaluate the status of the entire gastric mucosa Several studies suggest that serum PG levels may be a more objective and reliable indicator of the extent of chronic atrophic gastritis and a useful marker for detecting gastric cancer. [9] [10] [11] [12] [13] Since serum PG levels have been used as non-invasive "serological biopsy," we hypothesised that serum PG levels could indicate the development of metachronous gastric neoplasm after endoscopic resection of EGC. Therefore, the objective of this retrospective cohort study was to assess the effect of H. pylori eradication on gastric mucosal atrophy, as indicated by serum PG levels, and to evaluate the efficacy of serum PG levels as a predictive screening marker for metachronous gastric neoplasm development.
| ME TH ODS
This study was approved by the University Hospital Kyungpook
Trust (KNUMC_13-1059) and conducted in accordance to the principles of the Declaration of Helsinki. The study was reported according to STROBE guidelines and registered with ClinicalTrials.gov (No. NCT02682446). All authors had access to the study data and reviewed and approved the final manuscript.
| Patient selection
This single-centre cohort study included all consecutive patients in our prospectively maintained endoscopic submucosal dissection database system who underwent endoscopic submucosal dissection for EGC at the Kyungpook National University Medical Center, Daegu, South Korea between January 2008 and May 2013. Inclusion criteria were as follows: the serum PG concentration and H. pylori status measured at the time of endoscopic submucosal dissection and evidence of pathologically complete en bloc resection after endoscopic resection for EGC. Exclusion criteria were as follows: a previous history of endoscopic resection, gastrectomy or esophagectomy; proven pathologically incomplete resection or lymphovascular invasion in the resected endoscopic submucosal dissection specimen;
an additional operation after endoscopic submucosal dissection; failure to follow-up within 2 years; and continuous use of drugs that can affect serum PG levels, namely, proton pump inhibitors. All the patients provided written consent for the present study.
| Serological analyses at time of endoscopic resection
In routine laboratory tests before endoscopic submucosal dissection, sera were obtained from fasting blood samples. Serum PG levels were analysed by immediately centrifuging the samples at 4°C, storing the serum at À20°C, and the serum PG I and II levels were then measured using a chemiluminescent immunoassay (CLEIA) with the ARCHITECT analyzer (Wako Pure Chemical Industry, Osaka, Japan).
Previously established serum PG cut-off points for screening gastric cancer were used as potential predictors of metachronous gastric neoplasm development, specifically PG I ≤70 ng/mL, PG I ≤50 ng/mL, PG 
| Statistical analyses
The whole patient cohort was divided into several groups for statistical analysis. Patients were divided into three groups based on their H. pylori infection status at time of endoscopic submucosal dissection: negative, positive, and previous H. pylori infection groups.
Patients who were infected at time of endoscopic resection were subdivided according to whether or not the infection was successfully eradicated or persistent during follow-up surveillance. Patients whose PG levels had been monitored for at least 2 years were then selected from the main cohort. All continuous variables were expressed as mean AE standard deviation. All categorical variables were expressed as number and percentage. Patient groups were compared in terms of continuous and categorical variables using chisquared test and two-sample t-test for comparisons between two groups or one-way (analysis of variance) ANOVA with Tukey HSD test for multiple comparisons. To determine whether there was a significant change from baseline, in serum PG I levels and the serum ratio of PGI:PGII after eradication of H. pylori infection, paired t-test was used if normality was satisfied; else, Wilcoxon signed-rank test was used. The cumulative incidence of metachronous gastric neoplasm was calculated using the Kaplan-Meier method. The differences between groups were assessed using the log-rank test.
Multivariate analysis using both the Cox proportional hazard model and the logistic regression model was performed to identify factors that influenced the risk of metachronous gastric neoplasm development after endoscopic resection for EGC. In multivariate analysis, hazard ratios (HRs) and odds ratio (ORs) were adjusted for potentially confounding factors, such as, age (<60, 60-65 or ≥65 years), sex, serum PG level (PG I ≤ 30 or >30), initial serum ratio of PGI:
PGII ( ≤3 or >3), and mean serum PG level (PG I ≤30 or >30) or serum ratio of PGI:PGII ( ≤3 or >3) during follow-up surveillance.
HRs, ORs, and 95% confidence intervals (CIs) were calculated. To determine the number of patients to be treated for H. pylori infection to prevent one case of metachronous gastric neoplasm or metachronous gastric cancer, the number needed to treat (NNT) was calculated. All statistical analyses were performed using SPSS software (version 20.0, SPSS, Chicago, IL, USA). A two-tailed P < .05
was considered statistically significant.
3 | RESULTS
| Baseline characteristics of the whole cohort
During the study period, 590 patients were enrolled in the main cohort ( Figure 1 ). The baseline characteristics of these three groups are shown in (Figure 2 ).
Sixty-four patients with metachronous gastric neoplasm were significantly more likely to have persistent H. pylori infection (P = .008), serum PG I levels of ≤30 ng/mL (P = .004), and ratio of PGI:PGII ≤3
(P = .002) at the time of endoscopic submucosal dissection (Table 1) .
Kaplan-Meier analysis of the cumulative incidence of metachronous gastric neoplasm in the four H. pylori infection groups indicated that patients with persistent infection had a higher incidence of metachronous gastric neoplasm than those in the eradicated group (P = .001) and previous infection group (P = .021). Furthermore, negative infection group had a higher incidence of metachronous gastric neoplasm than those in the eradicated group (P = .012, Figure 3) .
Furthermore, the analysis indicated that patients with lower PG I levels (P = .007, Figure 4 ) and serum ratio of PGI:PGII ≤3 (P = .002, Figure 5 ) at baseline were more likely to develop metachronous gastric neoplasm.
Cox proportional hazard models showed that persistent H. pylori 
| Changes in serum PG levels after endoscopic resection
In 442 of the 590 cohort patients (74.9%), serum PG levels were followed up for 2 or more years. The negative (n = 54) and eradicated (n = 284) H. pylori group exhibited a significant increase in the serum ratio of PGI:PGII (P <.001 and P = .048) relative to the baseline value ( Figure S1 A & C). By contrast, the previous (n = 85) and persistent H.
pylori infection (n = 19) groups did not exhibit any significant changes in ratio of PGI:PGII (Figure S1 B & 1D) . To evaluate the effect of H.
pylori eradication on advanced gastric mucosal atrophy, the patients who had an initial serum ratio of PGI:PGII of ≤3 were assessed in terms of change in serum ratio of PGI:PGII after endoscopic resection.
The serum ratio of PGI:PGII increased in the successful H. pylori eradication group (P <.001), but not in the persistent H. pylori infection group (P = .167) ( Figure S2 ). However, these two subgroups did not show statistical significance in terms of metachronous gastric neoplasm incidence (13.2%, 20/131 vs 36.4%, 4/11; P = .060).
| Risk factors for metachronous gastric
neoplasm during surveillance in patients whose PG levels were followed of ≤30 ng/mL during follow-up (P = .013). They were also more likely to have persistent mean ratio of PGI:PGII ≤3 during follow-up (P = .001) ( Table 2 ). Logistic regression analysis showed that persistent H. pylori infection (OR = 4.404, 95% CI = 1.4535-13.348; P = .009) and persistent mean serum ratio of PGI:PGII ≤3
(OR = 2.141, 95% CI = 1.039-4.411; P = .039) were independent risk factors for metachronous gastric neoplasm development after endoscopic resection for EGC (Table 3) .
| DISCUSSION
Several recent cohort studies 3, [19] [20] [21] and a prospective open-label randomised trial 6 have suggested that H. pylori eradication may not significantly reduce the incidence of metachronous gastric neoplasm after endoscopic resection. Furthermore, histological degree of gastric atrophy is a well-known and significant risk factor for metachronous gastric neoplasm development, making its measurement an important predictor of metachronous gastric neoplasm development after endoscopic resection.
The current cohort study is the first article to show an effect of Figure S1 ), possibly indicating that the status of gastric mucosa is improved by H. pylori eradication and that this could be used to prevent the development of metachronous gastric neoplasm. However, these changes were not observed in the persistent H. pylori group. In addition, the study showed that patients with a persistent H. pylori infection were more likely to develop metachronous gastric neoplasm after endoscopic submucosal dissection than those who had previous H. pylori infections or whose infections were eradicated (Figure 3 ). Cox proportional hazard analysis also showed that persistent H. pylori infection (HR = 2.532) was an independent risk factors of metachronous gastric neoplasm. These observations support the notion that eradication may inhibit metachronous gastric neoplasm development of by improving gastric mucosal atrophy. The serum ratio of PGI:PGII of ≤3 at the time of endoscopic resection was also deemed an independent risk factors of metachronous gastric neoplasm in our study (HR = 1.881). During subgroup analysis, if the mean serum ratio of PGI:PGII remained ≤3 during follow-up (OR = 2.141), it was also an independent predictor of metachronous gastric neoplasm. Since the measurement of serum PG levels is cost-effective, minimally invasive, T A B L E 1 Risk factors for the development of metachronous gastric neoplasm after endoscopic submucosal dissection for early gastric cancer in the whole cohort The data are expressed as mean AE SD or n (%), as appropriate. MGN, metachronous gastric neoplasm; ESD, endoscopic submucosal dissection; F, female; H. pylori, Helicobacter pylori; M, male; SD, standard deviation; SM, submucosa; PG, pepsinogen.
a The groups were compared using the Chi-squared test or independent t-test, as appropriate.
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and quick and easy to perform, it has been considered to be suitable biomarker for gastric cancer screening in populations at high risk. 12, 22 Two Japanese studies 23, 24 showed that lower pre-endoscopic submucosal dissection ratio of PGI:PGII were significantly associated with metachronous gastric cancer development regardless of H. pylori status. Together with this study, these observations suggest lower serum ratio of PGI:PGII (≤3 or 3.3) at time of endoscopic resection can be useful predictive biomarkers for assessing risk of metachronous gastric neoplasm development in patients undergoing endoscopic
resection. However, it should be noted that serum PG levels are F I G U R E 3 Kaplan-Meier curves showing the cumulative incidence of metachronous gastric neoplasm in patients with H. pylori status during the surveillance after endoscopic resection The incidence of metachronous gastric neoplasm after endoscopic submucosal dissection was higher in the persistent H. pylori infection group compared to the eradicated group (P = .001) and the previous H. pylori infection group (P = .021). In addition, the negative H. pylori group has a higher incidence of metachronous gastric neoplasm compared to the eradicated group (P = .012). However, there was no statistical significance between the persistent and the negative H. pylori infection groups (P = .364), the persistent and the previous H. pylori infection groups (P = .190), and the previous H. pylori infection and the eradicated group (P = .387) ESD, endoscopic submucosal dissection; MGN, metachronous gastric neoplasm F I G U R E 4 Kaplan-Meier curves showing the cumulative incidence of metachronous gastric neoplasm in patients based on the serum PG I levels during the surveillance period. The incidence of metachronous gastric neoplasm after endoscopic submucosal dissection was higher in the PG I levels of ≤30 ng/mL group compared to the PG I levels of >30 ng/mL group (P = .007). The whole cohort (n = 590) was employed in this analysis. The differences between the groups were assessed using the log-rank test. ESD, endoscopic submucosal dissection; PG, pepsinogen influenced by various conditions. 25 Thus, to reduce the impact of these factors on the ability of PG levels to predict metachronous gastric neoplasm after endoscopic resection, serum PG levels should be measured before and after endoscopic resection. Previous study reported that PG I levels dropped significantly at 2 months after the eradication. By 12 months and 24 months post-eradication, they had risen again. 26 However, this study's subgroup analysis of PG levels in patients during serial follow-up suggests a persistent mean serum ratio of PGI:PGII ≤3 can be a useful screening tool to predict metachronous gastric neoplasm development after endoscopic submucosal dissection.
In this study, in patients with severe gastric atrophy at time of endoscopic resection (defined by PGI:PGII ≤3), successful H. pylori eradication raised the serum ratio of PGI:PGII in comparison to the baseline; and, it seemed to influence metachronous gastric neoplasm rates although the statistical significance was not meaningful in this study (P = .060). Nevertheless, the lack of statistically significant differences due to these relatively large numerical variations (13% vs 36%) may be merely due to a beta error, a consequence of the small sample size. Consequently, the results support the notion that H.
pylori eradication may not always reduce metachronous gastric neoplasm development after endoscopic resection, indicating that when damage to the gastric mucosa is so extreme, progression towards malignancy cannot be stopped by eradication. 27 Thus, moderate to severe mucosal atrophy or intestinal metaplasia may represent the "point of no return" at which the development of gastric cancer can no longer be prevented by just eradication of H. pylori infection. F I G U R E 5 Kaplan-Meier curves showing the cumulative incidence of metachronous gastric neoplasm based on the serum ratio of PGI:PGII levels during the surveillance period The incidence of metachronous gastric neoplasm after endoscopic submucosal dissection was higher in the PGI:PGII ≤3 group compared to the PGI:PGII >3 group (P = .002). The whole cohort (n = 590) was employed in this analysis. The differences between the groups were assessed using the log-rank test. ESD, endoscopic submucosal dissection; PG, pepsinogen This study has some limitations. First, it has a retrospective design and the number of persistent H. pylori infection group was small compared with the eradicated group. However, because all data were collected prospectively based on our endoscopic submucosal dissection database system, the selection bias would be minimal. Second, we could not evaluate the gastric mucosa status by biopsy. This might have resulted in difficulties in validating the correlation between serum PG levels and gastric atrophy. However, several previous studies have validated this correlation. [30] [31] [32] Finally, changes in serum PG levels after endoscopic resection could be influenced by many confounding factors, such as the use of PPIs.
We have tried to decrease these confounding factors during the surveillance period and analysed the mean serum ratio of PGI:PGII;
however, there remains a possibility of bias because of the retrospective design of the study and remained the issue whether changing PG levels over time were due to development of new lesions or from external confounding factors.
Despite these limitations, this study had several advantages over other studies in terms of understanding the development of metachronous gastric neoplasm after ER. We followed up 74.9% of the patients whose serum PG levels were tested at the time of endoscopic submucosal dissection so that we could evaluate the effect of H. pylori eradication on serum PG levels during follow-up. Although the histology of biopsy samples is still the de facto gold standard for measuring background gastric mucosal atrophy, we found that the serum ratio of PGI:PGII might have potential as a good indicator of the development of metachronous gastric neoplasm in the remnant stomach after endoscopic resection for EGC. Furthermore, most previous studies divided the patients at ER into three groups, namely, the uninfected, eradicated, and persistent H. pylori groups. 1, 5 By contrast, we finely categorised the patients into four subgroups at the time of endoscopic resection on the basis of serum H. pylori IgG, the rapid urea test, and histology, namely, the uninfected, previously infected, persistently infected, and eradicated groups. This method enabled us to examine the more subtle effects of H. pylori eradication after ER.
In conclusion, H. pylori eradication effectively reduced the risk of metachronous gastric neoplasm and the post-endoscopic resection serum PG level has potential as a predictive indicator of the development of metachronous gastric neoplasm after endoscopic resection.
